NURO Stock Overview
A commercial stage neurotechnology company, engages in designing, building, and marketing medical devices that stimulate and analyze nerve response for diagnostic and therapeutic purposes in the United States, Europe, Japan, and China. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
NeuroMetrix, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$4.39 |
| 52 Week High | US$4.73 |
| 52 Week Low | US$2.66 |
| Beta | 2.19 |
| 1 Month Change | 4.22% |
| 3 Month Change | 3.97% |
| 1 Year Change | 41.08% |
| 3 Year Change | -87.33% |
| 5 Year Change | -77.34% |
| Change since IPO | -100.00% |
Recent News & Updates
Recent updates
NeuroMetrix reports Q3 results
Oct 20NeuroMetrix: Strong Unit Economics, Accelerating Growth; Possibly Worth $15 In 5 Years
Sep 23NeuroMetrix GAAP EPS of -$0.17, revenue of $2.1M
Jul 21We're Hopeful That NeuroMetrix (NASDAQ:NURO) Will Use Its Cash Wisely
May 11
Here's Why We're Not Too Worried About NeuroMetrix's (NASDAQ:NURO) Cash Burn Situation
Jan 19NeuroMetrix: Solving Unmet Needs In Diagnostics And Therapeutic Neurostimulation
Sep 09We're Hopeful That NeuroMetrix (NASDAQ:NURO) Will Use Its Cash Wisely
Jul 21NeuroMetrix (NASDAQ:NURO) Is In A Good Position To Deliver On Growth Plans
Jan 27
Shareholder Returns
| NURO | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | 0.2% | -0.3% | -2.2% |
| 1Y | 41.1% | 10.0% | 18.3% |
Return vs Industry: NURO exceeded the US Medical Equipment industry which returned 10% over the past year.
Return vs Market: NURO exceeded the US Market which returned 18.3% over the past year.
Price Volatility
| NURO volatility | |
|---|---|
| NURO Average Weekly Movement | 4.1% |
| Medical Equipment Industry Average Movement | 7.8% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 17.8% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: NURO has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: NURO's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1996 | 26 | Shai Gozani | www.neurometrix.com |
NeuroMetrix, Inc., a commercial stage neurotechnology company, engages in designing, building, and marketing medical devices that stimulate and analyze nerve response for diagnostic and therapeutic purposes in the United States, Europe, Japan, and China. Its marketed products include DPNCheck, a nerve conduction test that is used to evaluate peripheral neuropathies, such as diabetic peripheral neuropathy; Quell, a wearable device for symptomatic relief and management of chronic pain; and ADVANCE system offers services to device and provide disposable electrodes to a customer base of hand surgeons and manufacturers for industrial health use. The company offers its products to managed care organizations, endocrinologists, podiatrists, and primary care physicians; occupational health, primary care, internal medicine, orthopedic, and hand surgeons; and pain medicine physicians, neurologists, physical medicine and rehabilitation physicians, and neurosurgeons.
NeuroMetrix, Inc. Fundamentals Summary
| NURO fundamental statistics | |
|---|---|
| Market cap | US$8.96m |
| Earnings (TTM) | -US$7.68m |
| Revenue (TTM) | US$3.77m |
2.4x
P/S Ratio-1.2x
P/E RatioIs NURO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| NURO income statement (TTM) | |
|---|---|
| Revenue | US$3.77m |
| Cost of Revenue | US$1.57m |
| Gross Profit | US$2.20m |
| Other Expenses | US$9.88m |
| Earnings | -US$7.68m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -3.76 |
| Gross Margin | 58.40% |
| Net Profit Margin | -203.71% |
| Debt/Equity Ratio | 0% |
How did NURO perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/02/23 06:17 |
| End of Day Share Price | 2025/02/21 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
NeuroMetrix, Inc. is covered by 5 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Robert Wasserman | Dawson James Securities |
| Andrew Fein | H.C. Wainwright & Co. |
| Anthony Vendetti | Maxim Group |